SOURCE: Plandaí Biotechnology, Inc.

Plandaí Biotechnology, Inc.

April 07, 2016 07:00 ET

Plandai Biotechnology, Inc. Announces First Shipment of Product to USA Customers

LONDON, UNITED KINGDOM--(Marketwired - Apr 7, 2016) -  Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® catechin complex, today announced that it has commenced shipping product to customers in the United States, a first for the London-based company that has thus far primarily sold in Africa and Western Europe. The first order, to be delivered by the end of April, will be formulated into nutriceutical products to be sold in the US and elsewhere by Ultimate Sports Nutrition (www.usn.co.za).

Callum Cottrell-Duffield, Vice President of Sales and Marketing for Plandaí, stated, "Production is now at the level where we feel comfortable supplying the US market on top of the other regions where we are actively selling. As an ingredient supplier, it is critical that we ensure adequate supply for our customers so that we never hold up their manufacturing processes. USN has been a valued partner since we first launched Phytofare® and we have been in continual contact to determine the best time to launch in America. We are enthused that our production has been stable and that very soon our investors, and those who have been following our progress for the past few years, will be able to go to their local stores and purchase products containing Phytofare®. Establishing a foothold in the US, first by partnering with a major distributor in AIDP as announced last week, and now with shipping our first significant amount of product to a US customer, is a huge milestone for Plandaí."

Phytofare®, which is produced from live green tea harvested on the Company's tea estate in northern South Africa, has been clinically shown in double blind human studies to have ten times the level of bioavailability over generic green tea extracts. Not only is Phytofare® better absorbed in the bloodstream, all eight catechins are present where they remain at therapeutic levels for over 24 hours. Generic extracts, by comparison, were shown to have only two catechins, both of which were absent from the system after four hours. This difference means that consumers of Phytofare® can take much smaller doses and achieve greater clinical outcomes.

For trade enquiries please email: info@phytofare.com

About Plandaí Biotechnology, Inc.

Plandaí Biotechnology, Inc. and its subsidiaries develop highly phyto-available™ extracts. Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its proprietary Phytofare® extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutriceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at http://www.sec.gov.

Contact Information

  • Contact:
    Hannah Merrill
    (917)900-6829